Sera Prognostics, Inc, a Salt Lake City, Utah-based developer of women’s health diagnostics to improve the health of pregnant women and newborns, received a $10m debt facility from Square 1 Bank.
The company intends to use the proceeds to increase its commercialization efforts.
In 2015, Sera will launch thr PreTRMTM test, which uses a routine blood sample obtained during the second trimester of pregnancy to provide an early and individualized assessment of a woman’s risk of preterm birth. Upon launch in the U.S., commercial testing will be performed at its CLIA laboratory with results returned to referring physicians.
The test will enable physicians to better understand the individualized risk of preterm birth earlier during pregnancy to personalize the care given to pregnant women.
FinSMEs
03/03/2015